Literature DB >> 1280476

The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons.

R G Andrews1, W I Bensinger, G H Knitter, S H Bartelmez, K Longin, I D Bernstein, F R Appelbaum, K M Zsebo.   

Abstract

Recombinant human stem cell factor (SCF), the ligand for c-kit, has been shown to stimulate increased numbers of hematopoietic progenitor cells of multiple types to circulate in the blood of baboons, but it was not known if the cells stimulated to circulate by SCF contained cells capable of engrafting and rescuing lethally irradiated baboons. Peripheral blood mononuclear cells (PBMNC) were collected by leukapheresis from four untreated control baboons and from three baboons on the 10th or 11th day of treatment with SCF (200 micrograms/kg/d). All animals were transplanted with 1.00 to 1.04 x 10(8)/kg of cryopreserved autologous PBMNC after treatment with a single dose of 1,020 cGy total body irradiation (TBI). Three animals were transplanted with PBMNC that had been collected during SCF treatment, 24 to 38 days after the last dose of SCF. Rapid trilineage engraftment was documented by bone marrow biopsy in all three. The mean time to a total white blood cell count (WBC) > or = 500/microL, WBC > or = 1,000/microL, and an absolute neutrophil count (ANC) > or = 500/microL was 15 +/- 3 (mean +/- SD), 19 +/- 1, and 19 +/- 2 days, respectively. Two animals remain alive with stable engraftment more than 180 and 245 days posttransplant. The third died of sepsis 32 days posttransplant with a hypercellular marrow showing trilineage engraftment. The surviving animals were transfusion independent by 10 and 59 days posttransplant. Four control animals were transplanted with PBMNC collected in the absence of SCF stimulation. One was treated for 11 days with SCF (200 micrograms/kg/d) after PBMNC were collected. This animal was transplanted 25 days after the last dose of SCF. None of the four control animals engrafted and they died 13, 16, 28, and 38 days posttransplant with marrow aplasia. Treatment with SCF stimulates the circulation of cells that engraft and rescue lethally irradiated baboons. The characteristics of the transplantable cells present in the circulation are now amenable to direct study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280476

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin.

Authors:  T Papayannopoulou; B Nakamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

2.  Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor.

Authors:  C E Dunbar; N E Seidel; S Doren; S Sellers; A P Cline; M E Metzger; B A Agricola; R E Donahue; D M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation.

Authors:  Z Zhang; R Zhang; A Joachimiak; J Schlessinger; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo.

Authors:  W H Fleming; E J Alpern; N Uchida; K Ikuta; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 5.  Cytokines and bone marrow transplantation.

Authors:  F Takaku
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Cobalt protoporphyrin IX increases endogenous G-CSF and mobilizes HSC and granulocytes to the blood.

Authors:  Agata Szade; Krzysztof Szade; Witold N Nowak; Karolina Bukowska-Strakova; Lucie Muchova; Monika Gońka; Monika Żukowska; Maciej Cieśla; Neli Kachamakova-Trojanowska; Marzena Rams-Baron; Alicja Ratuszna; Józef Dulak; Alicja Józkowicz
Journal:  EMBO Mol Med       Date:  2019-11-11       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.